CANF
Can-Fite BioPharma Ltd. AMEX$3.32
After hrs
$3.85
+10.00%
Mkt Cap $1.8M
52w Low $2.83
2.3% of range
52w High $24.00
50d MA $3.55
200d MA $7.85
P/E (TTM)
-0.2x
EV/EBITDA
0.2x
P/B
0.4x
Debt/Equity
0.0x
ROE
-175.8%
P/FCF
-0.4x
RSI (14)
—
ATR (14)
—
Beta
-0.10
50d MA
$3.55
200d MA
$7.85
Avg Volume
698.5K
About
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also devel…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 28, 2025 | AMC | — | -0.21 | — | 13.20 | -1.5% | -4.5% | +0.0% | +0.0% | -1.5% | -1.5% | — |
| Apr 14, 2025 | AMC | -0.24 | -0.21 | +10.7% | 26.00 | -2.3% | -3.1% | -5.4% | -7.7% | -4.6% | -10.0% | — |
| Dec 26, 2024 | AMC | -0.27 | -0.43 | -59.3% | 30.40 | -0.7% | +3.9% | +1.3% | +7.2% | +17.8% | +19.1% | — |
| Sep 26, 2024 | AMC | -0.36 | -0.40 | -11.1% | 41.00 | +0.0% | -1.5% | -2.0% | -4.9% | -4.4% | -4.9% | — |
| Jun 27, 2024 | AMC | -0.40 | -0.65 | -62.5% | 51.20 | +1.6% | +0.8% | +2.0% | -6.2% | -5.5% | -5.5% | — |
| Mar 28, 2024 | AMC | -5.40 | -6.20 | -14.8% | 44.40 | +3.2% | +4.1% | +1.4% | +3.2% | +5.0% | +5.9% | — |
| Nov 30, 2023 | AMC | -8.60 | -8.60 | +0.0% | 47.00 | -1.7% | +3.8% | -1.3% | -4.3% | -1.7% | -5.5% | — |
| Aug 31, 2023 | AMC | -10.80 | -8.00 | +25.9% | 58.80 | -2.0% | -2.4% | +2.7% | -4.4% | -4.8% | -5.4% | — |
| Jun 1, 2023 | AMC | -1.52 | -13.00 | -755.3% | 53.60 | +1.1% | +4.1% | +8.6% | +7.8% | -2.6% | +0.4% | — |
| Mar 30, 2023 | AMC | -11.40 | -22.20 | -94.7% | 48.60 | -4.9% | -5.8% | -9.5% | -11.1% | -11.9% | -10.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 24 | D. Boral Capital | Downgrade | Buy → Hold | — | $4.81 | $4.00 | -16.8% | -24.9% | -11.0% | -28.7% | -23.7% | -16.8% |
| Dec 17 | D. Boral Capital | Maintains | Buy → Buy | — | $5.78 | $5.66 | -2.1% | -5.4% | -13.5% | -12.8% | -15.4% | -16.8% |
| Nov 18 | D. Boral Capital | Maintains | Buy → Buy | — | $7.20 | $11.00 | +52.8% | +5.6% | -8.3% | -13.9% | -19.4% | -8.3% |
| Sep 16 | D. Boral Capital | Maintains | Buy → Buy | — | $13.00 | $13.20 | +1.5% | +0.0% | +0.0% | +0.0% | +0.0% | -3.1% |
| Sep 2 | D. Boral Capital | Maintains | Buy → Buy | — | $12.60 | $12.80 | +1.6% | +4.8% | +4.8% | +3.2% | +3.2% | +4.8% |
| Jul 29 | D. Boral Capital | Maintains | Buy → Buy | — | $14.00 | $14.20 | +1.4% | +1.4% | -2.9% | -4.3% | -5.7% | -4.3% |
| Apr 15 | D. Boral Capital | Maintains | Buy → Buy | — | $26.00 | $25.40 | -2.3% | -3.1% | -5.4% | -7.7% | -4.6% | -10.0% |
| Mar 21 | D. Boral Capital | Maintains | Buy → Buy | — | $30.20 | $30.60 | +1.3% | +6.0% | +7.3% | +4.0% | +0.7% | +2.0% |
| Mar 20 | D. Boral Capital | Maintains | Buy → Buy | — | $32.60 | $32.20 | -1.2% | -7.4% | -1.8% | -0.6% | -3.7% | -6.7% |
| Mar 18 | D. Boral Capital | Maintains | Buy → Buy | — | $33.00 | $38.00 | +15.2% | +22.4% | -1.2% | -8.5% | -3.0% | -1.8% |
Data updated apr 26, 2026 10:04am
· Source: massive.com